C2i Genomics Acquires CLIA-Certified Lab to Accelerate Commercialization of Cancer Intelligence Platform

C2i Genomics, the world’s first platform utilizing whole-genome pattern recognition for cancer intelligence, has acquired QNA Dx, a CLIA-certified sequencing laboratory located in Cambridge, MA for an undisclosed amount. This move comes just a month after the company made several key hires and will help the company rapidly scale and commercialize its whole genome sequencing cancer detection solution. 

Being a world-class sequencing laboratory in the heart of the Boston biotechnology ecosystem, QNA Dx will help C2i Genomics scale its clinical capacity to process samples from cancer patients. C2i Genomics has developed an automated platform for cancer detection and response to treatment monitoring while QNA Dx performs its NGS-based diagnostic tests as a CLIA-certified lab. The acquisition, therefore, enables C2i Genomics to adopt a dual business model comprised of both centralized lab services and platform-based distributed service, opening a reimbursement pathway for clinicians who want to use its technology to replace current MRD tests to monitor and optimize cancer treatment efficacy. 

C2i’s cancer intelligence technology works by applying whole-genome sequencing and artificial intelligence to just a 2ml blood sample to provide up to 100x more sensitive cancer detection than competing technologies. This technology also eliminates the need to develop a patient-specific assay, enabling high precision monitoring with reduced logistic complexity and rapid turnaround times. The merger will enable C2i Genomics to expand its research and discovery services towards transforming patient care by providing cutting-edge treatment monitoring in the clinical diagnostic settings. 

“Bringing the world-class resources and expertise of QNA Dx to the C2i family will significantly help us scale our ability to bring our cancer intelligence platform to the clinic,” said Asaf Zviran, co-founder and CEO of C2i Genomics. “In the past 6 to 12 months, we’ve seen early adopters using the C2i cancer detection platform as a clinical research tool (RUO) in genomic labs across the US, EU and Singapore. Still, our principal motivation remains to transform patient care and take the technology to the clinic. In this expansion, we essentially generate a direct centralized lab diagnostic channel for clinical use and reimbursement.” 

Since QNA Dx, as a CLIA-certified testing laboratory, already was performing Whole-Exome and Whole-Genome genetic testing, this acquisition brings together a complementary and synergistic set of skills. As part of the acquisition, all of QNA Dx’s assets and employees will join C2i Genomics. The company is going to continue the operations of the laboratory and use the acquired capabilities to expand its offering, release an MRD LDT and seek reimbursement approval.

“By combining our next-generation genome sequencing expertise with C2i Genomics’ AI-based pattern recognition platform, we’re thrilled to help supercharge cancer detection for our patients,” said Eric White, Senior Director of the QNA Dx Laboratory. “By providing a robust and timely cancer detection with superior sensitivities to legacy systems, we’re honored for the opportunity to help improve patient outcomes and save lives.”

For companies interested in partnering or using C2i’s cancer intelligence technology or anybody interested in working at C2i, please visit c2i-genomics.com. 

About C2i Genomics 

Founded in 2019, C2i Genomics has created the world’s leading cancer treatment intelligence platform that uses low-input blood (only 2mL blood) whole-genome sequencing to provide 100x more sensitive detection than competing liquid biopsy companies. With a headquarters in NYC and an R&D center in Israel, C2i’s SaaS solution utilizes a cloud-based platform to perform cancer tumor burden monitoring on a global scale, leveraging the thousands of already installed genome sequencers around the world. Using cutting-edge scientific breakthroughs, growing genomic and clinical databases, and sophisticated computation and AI, C2i enables high precision personalized medicine, reduced cancer treatment costs, and accelerated drug development. The firm is backed by top life sciences investors including Casdin Capital, NFX, and The Mark Foundation for Cancer Research. For more information, please visit c2i-genomics.com.

Contact Information

Riley Munks

Media Contact

VSC for C2i Genomics

rileym@vsc.co